Literature DB >> 9990475

Activity of clinafloxacin, trovafloxacin, quinupristin/dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin.

M A Cohen1, M D Huband.   

Abstract

Isolations of Staphylococcus aureus strains with reduced susceptibility to vancomycin are now being reported worldwide. In testing here by broth microdilution according to NCCLS guidelines and applying vancomycin breakpoint criteria (susceptible at 4 micrograms/mL), two of three strains were susceptible (MICs at 4 micrograms/mL) rather than intermediate (MICs at 8 micrograms/mL) as previously reported by other laboratories. Clinafloxacin was more active (MICs/MBCs at 0.5 to 2 micrograms/mL) than ciprofloxacin, grepafloxacin, levofloxacin, ofloxacin, and sparfloxacin. Trovafloxacin, trimethoprim/sulfamethoxazole, and quinupristin/dalfopristin were the next most active agents, although quinupristin/dalfopristin was bactericidal against only two of these three strains. Amikacin, imipenem, oxacillin, and rifampin were less active.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9990475     DOI: 10.1016/s0732-8893(98)00121-7

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  10 in total

1.  Staphylococcus aureus Endocarditis in the 21st Century.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

Review 2.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

3.  Quinupristin/dalfopristin: the first available macrolide-lincosamide-streptogramin antibiotic.

Authors:  C Gurk-Turner
Journal:  Proc (Bayl Univ Med Cent)       Date:  2000-01

4.  Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections.

Authors:  G Siami; N Christou; I Eiseman; K J Tack
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

5.  Drug interactions with clinafloxacin.

Authors:  E J Randinitis; C W Alvey; J R Koup; G Rausch; R Abel; N J Bron; N J Hounslow; A B Vassos; A J Sedman
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

6.  Pharmacokinetics of clinafloxacin after single and multiple doses.

Authors:  E J Randinitis; J I Brodfuehrer; I Eiseman; A B Vassos
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

7.  Clinafloxacin pharmacokinetics in subjects with various degrees of renal function.

Authors:  E J Randinitis; J R Koup; G Rausch; R Abel; N J Bron; N J Hounslow; A B Vassos; A J Sedman
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

8.  An efficient Bi(NO3)3 x 5H2O catalyzed multi component one-pot synthesis of novel naphthyridines.

Authors:  Tangali R Ravikumar Naik; Halehatty S Bhojya Naik
Journal:  Mol Divers       Date:  2008-06-28       Impact factor: 2.943

9.  The use of antimicrobial peptides in ophthalmology: an experimental study in corneal preservation and the management of bacterial keratitis.

Authors:  Mark J Mannis
Journal:  Trans Am Ophthalmol Soc       Date:  2002

Review 10.  Staphylococcus aureus Nasal Carriage and Autoimmune Diseases: From Pathogenic Mechanisms to Disease Susceptibility and Phenotype.

Authors:  Fulvia Ceccarelli; Carlo Perricone; Giulio Olivieri; Enrica Cipriano; Francesca Romana Spinelli; Guido Valesini; Fabrizio Conti
Journal:  Int J Mol Sci       Date:  2019-11-11       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.